Due to insufficient relevant studies, weneed to be cautious about the rankings this study received, according to SUCRA.For example, regarding the outcome of NTpro-BNP, only one study included theeffect of liraglutide on the reduction of NTpro-BNP levels in patients with HF.As a result, the utility of liraglutide was ranked first; thus, more clinicaltrials are needed to validate the efficiency of liraglutide. The gene discussed is NPPB; the disease is hydrops fetalis.